Introduction
============

COPD is a major cause of morbidity and mortality worldwide. According to the GOLD 2018, COPD is the fourth leading cause of death in the world and is projected to be the third by 2020.[@b1-copd-13-3191] There is no proven therapy to reverse pulmonary injury due to COPD, emphasizing the urgent need to explore novel targets to prevent disease progression.

Lung inflammation caused by recurrent pulmonary infection often leads to acute exacerbation of COPD (AECOPD).[@b2-copd-13-3191],[@b3-copd-13-3191] Innate immunity is the first line of defense against invading pathogens, and lymphocytes play pivotal roles in the regulation of immune response via either direct cell-to-cell interactions or secretion of cytokines, including tumor necrosis factor (TNF)-α, IL-12 p40, and interferon (IFN)-γ.[@b4-copd-13-3191]--[@b6-copd-13-3191] Currently, dysregulation of immunity is thought to be an important disease mechanism in COPD locally and systematically. Chronic infection or antigen presentation would cause abnormalities in the distribution and function of T-lymphocytes, resulting in the dysfunction of cell-mediated immune responses.[@b7-copd-13-3191],[@b8-copd-13-3191] Functional exhausted effector T cells expressing programmed cell death protein 1 (PD-1), a negative costimulatory molecule that is associated with defective immune response, increase in COPD patients.[@b9-copd-13-3191]

Glucagon-like peptide-1 (GLP-1) is a hormone secreted by L cells of the distal ileum in response to food intake.[@b10-copd-13-3191] GLP-1 receptor (GLP-1R) is a G-protein-coupled membrane receptor detected not only in the cells of the pancreatic islets but also in several other tissues such as the central nervous system, kidney, heart, blood vessels, and lung.[@b11-copd-13-3191],[@b12-copd-13-3191] Liraglutide (LIR), a GLP-1 analog, is a clinically used drug for metabolic syndromes with a wide knowledge in improving insulin sensitivity and anti-inflammatory function.[@b13-copd-13-3191],[@b14-copd-13-3191] In COPD, it has been found that activation of GLP-1R signaling by LIR could decrease the severity of AECOPD and airway remodeling,[@b15-copd-13-3191],[@b16-copd-13-3191] but the mechanism is not well known.

Recent studies suggested that the exacerbations of obstructive pulmonary disease and airway remodeling are closely associated with T-lymphocyte immune influences.[@b17-copd-13-3191],[@b18-copd-13-3191] It is also reported that GLP-1 can inhibit chemokine-induced differentiation of CD4-positive lymphocyte into TH1 cells.[@b19-copd-13-3191] It is reasonable to hypothesize that GLP-1R signaling is associated with the function of T-lymphocytes in COPD patients. Our results may provide a possible therapeutic approach for COPD via modulation of GLP-1R signaling.

Patients and methods
====================

Subjects
--------

We obtained peripheral blood from the patients of respiratory department in Ruijin Hospital affiliated to the School of Medicine, Shanghai Jiao Tong University. All COPD patients met the criteria proposed by GOLD 2018 and were in a stable condition at the time of the study. The non-COPD group comprised age-, sex-, and smoking history-matched non-COPD subjects randomly selected from Ruijin Physical Examination Center. These non-COPD subjects had normal pulmonary images, routine blood screening tests, and biochemical examination without any history of asthma or chronic bronchitis. Subject characteristics are summarized in [Table 1](#t1-copd-13-3191){ref-type="table"}. No patients were diagnosed with metabolic diseases or recent (8 weeks) respiratory tract infection or any exacerbations requiring oral steroid and nonsteroidal anti-inflammatory agents. All the subjects underwent clinical evaluation and pulmonary function test and provided written informed consent to participate in the study. The study was reviewed and approved by Ruijin Hospital Ethics Committee, Shanghai Jiao Tong University School of Medicine.

Isolation of peripheral blood mononuclear cells (PBMCs)
-------------------------------------------------------

Blood samples were collected in 5 mL EDTA evacuated test tubes (BD Vacutainer Systems, Plymouth, UK) from all subjects. After the plasma was isolated, PBMCs were separated from the peripheral blood using Lymphoprep™ (density gradient: 1.077±0.001 g/mL; Axis-Shield, Oslo, Norway) for 30 minutes at 800 *g*. The mononuclear layer was harvested and transferred to new tubes. PBS was added to the PBMCs, and the cells were washed twice by centrifugation for 10 minutes at 500 *g*. This study was conducted in two phases: 1) detection of GLP-1R expression was carried out in a cohort of COPD patients (n=40) and non-COPD (n=35) subjects and 2) fluorescence-activated cell sorter (FACS) analysis of PD-1 expression was evaluated in a different cohort of COPD patients (n=17) and non-COPD (n=16) subjects. LIR treatment was studied in a subset of patients who did not use inhaled corticosteroids (ICSs) as a current maintenance drug during the past 3 months and were current smokers in COPD (n=12) patients and non-COPD (n=12) subjects, depending on the availability of cells.

RNA extraction and real-time PCR
--------------------------------

RNA extraction and cDNA synthesis from PBMCs were performed using TRIzol reagents (Thermo Fisher Scientific, Waltham, MA, USA) and RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, Waltham, MA, USA), according to the manufacturer's protocol. Total RNA (500 ng) was amplified with a 7500 Fast Real-Time PCR System (Thermo Fisher Scientific) and performed with FastStart Universal SYBR Green (Hoffman-La Roche Ltd., Basel, Switzerland) for real-time PCR after cDNA synthesis. The standard curve for quantification was created with a previously described modified procedure.[@b20-copd-13-3191] The sequences of all primers used are as follows: hGLP-1R: sense 5′-ACCTGTCGGAGTGTGAAGAG-3′ and antisense 5′-GCGGAGAAAGAAGTGCGTA-3′; hIFN-γ: sense 5′-TCAACTTCTTTGGCTTAATTCTCTC-3′ and antisense 5′-ATATGGGTCCTGGCAGTAACA-3′.

Fold change of the gene expression was calculated by 2^−ΔCt^ relative to the internal reference gene (glyceraldehyde-3-phosphate dehydrogenase, *GAPDH*).

Western blotting
----------------

Briefly, 10^6^ PBMCs isolated from peripheral blood were lysed in 100 µL lysis buffer (P0013B; Beyotime, Suzhou, China) containing protease inhibitors. Equal amounts of proteins (30 µL) were subjected to a 10% SDS-PAGE and then transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). After blocking with Tris-buffered saline and Tween 20 containing 5% nonfat milk for 2 hours at room temperature, the membrane was incubated overnight at 4°C with mouse monoclonal anti-hGLP-1R antibody (1:500; sc-390774; Santa Cruz Biotechnology Inc., Dallas, TX, USA) or anti-rabbit GAPDH antibody (1:1,000; Cell Signaling, Danvers, MA, USA). The membrane was washed for 10 minutes with Tris-buffered saline and Tween 20 three times and then incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG antibody (1:1,000; Cell Signaling) for 1 hour at room temperature. After the membrane was washed, chemiluminescent substrate (Thermo Fisher Scientific) was applied. The signal was detected and quantified with an enhanced chemiluminescence system (ImageQuant LAS-4000 MINI; GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA).

PBMCs: in vitro treatment
-------------------------

Purified PBMCs (1×10^6^/mL) were resuspended in Roswell Park Memorial Institute (RPMI)-1640 complete medium containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin and then cultured with or without LIR (Victoza, Novo Nordisk, Denmark) at concentrations of 100 nM overnight (5% CO~2~ atmosphere at 37°C). After incubation, the cells were harvested for analysis of GLP-1R expression using quantitative real-time PCR (qRT-PCR) and Western blotting. The cells were also collected and assessed for PD-1 expression using flow cytometry. Mitogen stimulation of PBMCs was performed as described earlier.[@b21-copd-13-3191] Triplicate cultures of 10^5^ cells/well were stimulated with 10 µg/mL of phytohemagglutinin (PHA; Sigma-Aldrich Co., St Louis, MO, USA) in complete medium in 96-well, flat-bottomed microtiter plates (Corning Incorporated, Corning, NY, USA). Cells were either untreated or treated with LIR. After 3 days of stimulation, the culture supernatants were analyzed using an IFN-γ ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).

Cytokine ELISAs
---------------

The concentrations of IFN-γ in the plasma and the cell supernatant were detected using DuoSet ELISA kits (R&D Systems, Inc.) according to the manufacturer's instructions.

Flow cytometry staining and analysis
------------------------------------

Samples were immunostained with mAbs including CD3-FITC, CD4-PE, CD8-BV521, PD-1-BV421, and relevant isotype controls for 30 minutes at room temperature. All the antibodies were from BD Biosciences (San Jose, CA, USA). Cells were then resuspended in 1% paraformaldehyde (PFA) and stored at 4°C until flow cytometry could be conducted.

Statistical analyses
--------------------

Results were presented as mean ± standard error of the mean if not stated otherwise. Analysis of two groups was performed using Wilcoxon's signed-rank test for paired data and the Mann--Whitney test for unpaired data. The chi-squared test was used for categorical data. Spearman's rank correlation coefficients were evaluated to access the relationships between GLP-1R mRNA levels, IFN-γ expression levels, and clinical lung function parameters. *P*-values of \<0.05 were considered statistically significant. Statistical analyses were performed as shown in [Figures 1](#f1-copd-13-3191){ref-type="fig"}[](#f2-copd-13-3191){ref-type="fig"}[](#f3-copd-13-3191){ref-type="fig"}[](#f4-copd-13-3191){ref-type="fig"}--[5](#f5-copd-13-3191){ref-type="fig"}, using GraphPad Prism version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

GLP-1R level in PBMCs in COPD patients and non-COPD subjects
------------------------------------------------------------

We profiled the expression of GLP-1R in PBMCs at both the mRNA and protein levels. The expression level of GLP-1R in PBMCs was significantly lower in COPD patients than non-COPD subjects (*P*\<0.0001; [Figure 1](#f1-copd-13-3191){ref-type="fig"}). To ensure that the difference was not mixed by the effect of ICS, we also compared the expression level of GLP-1R in PBMCs of COPD patients based on ICS use and found no significant intergroup differences ([Figure S1A](#SD1-copd-13-3191){ref-type="supplementary-material"}).

Correlation between IFN production and GLP-1R expression
--------------------------------------------------------

We found that relative GLP-1R mRNA level of PBMCs had no correlation with lung function parameters of COPD patients, including FEV~1~/FVC% and predicted FEV~1~% ([Figure 2A and B](#f2-copd-13-3191){ref-type="fig"}). However, a positive correlation existed between GLP-1R mRNA level and IFN-γ mRNA level in COPD patients (*r*=0.5642, *P*\<0.001; [Figure 2C](#f2-copd-13-3191){ref-type="fig"}). Meanwhile, both FEV~1~/FVC% (*r*=0.49, *P*\<0.01) and predicted FEV~1~% (*r*=0.4848, *P*\<0.01) had moderate correlation with IFN-γ mRNA levels ([Figure 2D and E](#f2-copd-13-3191){ref-type="fig"}). Furthermore, IFN-γ production decreased in COPD patients when compared with non-COPD subjects ([Figure 2F and G](#f2-copd-13-3191){ref-type="fig"}). These results indicated that GLP-1R expression was associated with the functionality of lymphocytes.

Functionality of T cells after LIR treatment
--------------------------------------------

Previous studies reported that although LIR had therapeutic potential in COPD by decreasing the severity of acute exacerbations, it had had no modulation on pulmonary inflammation and surfactant production.[@b16-copd-13-3191] To ensure that GLP-1R signaling plays a critical role in enhancing effector T cell functionality of COPD patients, cytokine production of antigen-stimulated effector T cells was examined in the presence or absence of LIR. We first treated the COPD patients' PBMCs with LIR; GLP-1R expression in PBMCs was first examined to ensure a potential direct effect, as GLP-1R expression was proven to be upregulated after GLP-1R agonist or dipeptidyl peptidase 4 (DPP-4) inhibitor treatment in mice.[@b12-copd-13-3191],[@b22-copd-13-3191] As shown in [Figure 3](#f3-copd-13-3191){ref-type="fig"}, LIR administration promoted a 2.3- and 1.8-fold increase in the GLP-1R mRNA level of both COPD patients and non-COPD subjects as well as a significant increase in GLP-1R protein level of COPD patients. Meanwhile, LIR treatment resulted in an enhancement of IFN-γ production of PBMCs from COPD patients ([Figure 4A](#f4-copd-13-3191){ref-type="fig"}), suggesting that the activation of GLP-1R signaling could contribute to enhanced antibacterial immunity in COPD patients. The reduced secretion of IFN-γ by PBMCs from COPD patients was also confirmed by analyzing its production after PHA stimulation ([Figure 4B](#f4-copd-13-3191){ref-type="fig"}).

Downregulated PD-1 expression in COPD patients after LIR treatment
------------------------------------------------------------------

To further assess whether GLP-1R signaling has potential effects on ameliorating immunosuppression, we treated COPD patients' PBMCs with LIR and found that the addition of LIR downregulated PD-1 expression in both CD4 and CD8 T cells of COPD patients ([Figures 5A and B](#f5-copd-13-3191){ref-type="fig"} and [S2](#SD2-copd-13-3191){ref-type="supplementary-material"}). Meanwhile, the proportion of both PD-1^+^ CD4^+^ T cells (12.49±1.82 vs 9.97±1.55) and PD-1^+^ CD8^+^ T cells (4.01±0.51 vs 2.29±0.44) was greater in COPD patients than non-COPD subjects, although the difference in CD4^+^ T cell percentage did not reach statistical significance (*P*=0.40; [Figure 5C and D](#f5-copd-13-3191){ref-type="fig"}). No significant difference of PD-1 expression was found on lymphocytes from COPD patients based on ICS use ([Figure S1B and C](#SD1-copd-13-3191){ref-type="supplementary-material"}), which was consistent with the results conducted by the McKendry's group.[@b23-copd-13-3191]

Discussion
==========

Our study revealed that GLP-1R expression decreased in circulating PBMCs from COPD patients, which was associated with IFN-γ expression. The treatment with LIR could restore the defective IFN-γ production with PHA stimulation and downregulated the PD-1 expression in COPD T cells.

Prior study has documented the association between inflammation and GLP-1R signaling. Islets were less frequently found to be GLP-1R positive or expressed receptors in low density in chronic pancreatitis than in the normal pancreas.[@b24-copd-13-3191] COPD is widely recognized as a chronic inflammatory disease.[@b3-copd-13-3191]--[@b5-copd-13-3191],[@b25-copd-13-3191],[@b26-copd-13-3191] The principal pathogenesis of COPD airways is characterized by the presence of an inflammatory cellular infiltrate and remodeling of the airway wall, thereby resulting in the airway obstruction.[@b27-copd-13-3191],[@b28-copd-13-3191] As per the current concepts, COPD is increasingly being recognized as a whole systemic inflammatory disorder rather than an airway-located disease. The presence of airway and systemic inflammation in COPD has been suggested by multiple studies showing increased oxidative stress and circulating levels of inflammatory mediators.[@b29-copd-13-3191],[@b30-copd-13-3191] Sun et al[@b31-copd-13-3191] proved that GLP-1R expression levels were decreased in airway smooth muscle (ASM) cells from COPD patients compared with those from healthy subjects and upregulation of GLP-1R inhibited cell proliferation, migration, and inflammatory cytokine expression in ASM cells. In our study, we found that the expression level of GLP-1R was lower in PBMCs of COPD patients than non-COPD subjects, indicating that the impairment of GLP-1R signaling also occurred in circulating PBMCs of COPD patients.

GLP-1 and its analogs have been verified to play an obvious anti-inflammatory role in various diseases, including type 2 diabetes, asthma, and atherogenesis.[@b13-copd-13-3191],[@b14-copd-13-3191],[@b32-copd-13-3191] However, the therapeutic potential of the specific GLP-1R agonist -- LIR -- in COPD was only confirmed in a mice model of obstructive pulmonary disease induced by ovalbumin (OVA) and lipopolysaccharide (LPS).[@b16-copd-13-3191] We found that there was a positive correlation between IFN-γ production and GLP-1R expression. Meanwhile, PD-1-expressing lymphocyte populations were deceased and IFN-γ production was increased after LIR treatment, which suggests that restoring GLP-1R signaling might have regulatory effects on innate and adaptive immunity of COPD. Our finding is reminiscent of the GLP-1R signaling modulation in controlling innate immune responses and host microbial responses, as observed by Yusta et al[@b33-copd-13-3191] in a mouse model.

Emerging data suggest the immune deficiency of T cells in COPD.[@b9-copd-13-3191],[@b34-copd-13-3191],[@b35-copd-13-3191] Sustaining signaling in COPD can lead to progressive loss of T cell function. T cells from diseased lungs express the key receptor PD-1 and demonstrate loss of cytotoxicity.[@b23-copd-13-3191],[@b36-copd-13-3191] PBMCs from COPD patients show impaired responses to antigen, such as lipoprotein P6 and PHA stimulation.[@b9-copd-13-3191],[@b35-copd-13-3191],[@b37-copd-13-3191] COPD patients with more severe stage have lower proportions of IFN-γ CD8^+^ T cells than those with mild stage.[@b38-copd-13-3191] IFN-γ and its specific receptors have long been recognized as a critical component of innate immune defense to microorganisms and viruses.[@b5-copd-13-3191],[@b6-copd-13-3191],[@b39-copd-13-3191],[@b40-copd-13-3191] In keeping with these findings, we also found that PBMCs from COPD patients expressed lower IFN-γ mRNA than non-COPD subjects and showed greater occurrence of reduced IFN-γ production with the progression of COPD severity. A greater proportion of PD-1-expressing lymphocytes was seen in COPD patients, and impaired response of T cells toward PHA stimulation was found.

GLP-1R expression was reported to be downregulated in response to dexamethasone in islets,[@b22-copd-13-3191] and COPD patients in stable condition often use ICS combined with long-acting β2 agonists (LABAs) as the maintenance treatment. To rule out the possibility of ICS-induced differences in GLP-1R expression between COPD patients and non-COPD subjects, we evaluated the GLP-1R expression in COPD patients based on ICS use and found that there were no significant inter-group differences. We acknowledge that the observational nature of our study and the relatively small cohort sizes are significant limitations of our study. Another limitation is the heterogeneity of GOLD stages of the COPD patients. However, all the patients included in the study were in stable state and proportions of lymphocyte subpopulations did not significantly differ. Our data provided a plausible theory that restoration of GLP-1R signaling could ameliorate functional defect of T cells in COPD patients. As metabolic syndrome and diabetes are common comorbidities of COPD[@b41-copd-13-3191] and GLP-1 analogs have been clinically used in obesity and diabetes, more preclinical and clinical studies are required to be carried out to clarify the regulatory mechanism of GLP-1R signaling in COPD.

Conclusion
==========

We found that PBMCs from COPD patients underwent GLP-1R signaling defect, which was associated with decreased IFN-γ production. Treatment with LIR significantly restored the IFN-γ production of PBMCs and down-regulated the PD-1-expressing T cell proportions in these patients. These findings indicated that the restoration of GLP-1R signaling might ameliorate T cell dysfunction in COPD patients. It remains to be seen if GLP-1R signaling and GLP-1 analogs are likely to serve as possible immunomodulatory targets for COPD therapy.

Supplementary materials
=======================

###### 

GLP-1R and PD-1 expression in PBMCs of COPD patients based on ICS use.

**Notes:** (**A**) qRT-PCR analysis of GLP-1R mRNA expression in PBMCs of COPD patients based on ICS use. Data are expressed as mean ± SEM. (**B**) Frequency of CD4^+^ PD-1^+^ T cells and (**C**) frequency of CD8^+^ PD-1^+^ T cells in COPD patients based on ICS use. Data are expressed as mean ± SEM. ICS, COPD patients using ICS as a current maintenance drug for at least 3 months; no ICS, COPD patients using no ICS as a current maintenance drug during the past 3 months.

**Abbreviations:** GLP-1R, glucagon-like peptide-1 receptor; ICS, inhaled corticosteroid; PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death protein 1; qRT-PCR, quantitative real-time PCR; SEM, standard error of the mean.

###### 

Flow cytometry gating strategy for PD-1^+^ T cells in PBMCs.

**Notes:** (**A**--**C**) The gating method of FACS. Initial lymphocyte populations were gated through SSC vs FSC. (**B**, **C**) Through the CD3-FITC staining and CD8-BV521 vs CD4-PE plot, lymphocytes were further identified as CD3^+^ CD4^+^ and CD3^+^ CD8^+^ population. The Q1-LR section represents the CD3^+^ CD4^+^ population and the Q1-UL section represents the CD3^+^ CD8^+^ population. (**D**, **G**) Isotype control of PD-1 expression on CD3^+^ CD4^+^ and CD3^+^ CD8^+^ lymphocytes. (**D**) The section of P6 is the final result of PD-1 expression on CD3^+^ CD4^+^ and (**G**) the section of P5 is the final result on CD3^+^ CD8^+^ lymphocytes from COPD patients (**E**, **H**) and non-COPD subjects (**F**, **I**). Isotype control is set before each independent experiment.

**Abbreviations:** FACS, fluorescence-activated cell sorter; FSC, forward scatter; PBMCs, peripheral blood mononuclear cells; PD-1, programmed cell death protein; SSC, side scatter.
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![GLP-1R level in PBMCs of COPD patients and non-COPD subjects.\
**Notes:** (**A**) qRT-PCR analysis of GLP-1R gene expression of COPD patients (n=40) and non-COPD subjects (n=35). The hGLP-1R mRNA level was normalized to GAPDH control and multiplied by 10^4^. Data are expressed as mean ± SEM. \*\*\*\**P*\<0.0001 vs non-COPD. (**B**) Representative Western blot analysis for GLP-1R protein. (**C**) Fold change of densitometric analysis obtained from samples derived from COPD patients normalized to the average quantification of samples derived from non-COPD subjects. Numbers 1--7 represent individuals with COPD, and numbers I--V represent individuals with non-COPD. Data are expressed as mean ± SEM. \**P*\<0.05 vs non-COPD. The statistical significance of differences observed was determined by Mann--Whitney test.\
**Abbreviations:** GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLP-1R, glucagon-like peptide-1 receptor; PBMCs, peripheral blood mononuclear cells; qRT-PCR, quantitative real-time PCR; SEM, standard error of the mean.](copd-13-3191Fig1){#f1-copd-13-3191}

![GLP-1R and IFN-γ expression of PBMCs from COPD patients.\
**Notes:** (**A**) Correlation between predicted FEV~1~% and GLP-1R mRNA expression in PBMCs of COPD patients. (**B**) Correlation between FEV~1~/FVC% and GLP-1R mRNA expression in PBMCs of COPD patients. (**C**) Correlation between IFN-γ mRNA expression and GLP-1R mRNA expression in PBMCs of COPD patients. (**D**) Correlation between predicted FEV~1~% and IFN-γ mRNA expression in PBMCs of COPD patients. (**E**) Correlation between FEV~1~/FVC% and IFN-γ mRNA expression in PBMCs of COPD patients. (**F**) qRT-PCR analysis of IFN-γ mRNA expression in PBMCs of COPD patients and non-COPD subjects. The expression level was normalized to GAPDH control. Data are expressed as mean ± SEM. (**G**) ELISA of IFN-γ level in the plasma of COPD patients and non-COPD subjects. Data are expressed as mean ± SEM. \**P*\<0.05 vs non-COPD. The correlation was determined by Spearman's correlation analysis, and the statistical significance of differences observed was determined by Mann--Whitney test.\
**Abbreviations:** GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLP-1R, glucagon-like peptide-1 receptor; IFN, interferon; PBMC, peripheral blood mononuclear cell; qRT-PCR, quantitative real-time PCR; SEM, standard error of the mean.](copd-13-3191Fig2){#f2-copd-13-3191}

![GLP-1R expression of PBMCs after LIR treatment.\
**Notes:** (**A**) mRNA level analyzed by qRT-PCR; relative GLP-1R mRNA level is given as the ratio between the expression level before and after LIR treatment. Data are expressed as mean ± SEM (n=12). (**B**, **C**) Representative Western blot analysis for GLP-1R protein and the average quantification obtained by densitometric analysis of the samples before and after LIR treatment in COPD patients and non-COPD subjects. Data are expressed as mean ± SEM. \*\**P*\<0.01 vs control. The statistical significance of differences observed was determined by Wilcoxon matched-pairs signed-rank test.\
**Abbreviations:** con, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLP-1R, glucagon-like peptide-1 receptor; LIR, liraglutide; PBMC, peripheral blood mononuclear cell; qRT-PCR, quantitative real-time PCR; SEM, standard error of the mean.](copd-13-3191Fig3){#f3-copd-13-3191}

![IFN-γ production of PBMCs stimulated by PHA in COPD patients.\
**Notes:** (**A**) ELISA of PHA-stimulated IFN-γ level in the culture supernatants with or without LIR treatment overnight on PBMCs from COPD patients. Data are expressed as mean ± SEM (n=12). \**P*\<0.05 vs PHA-stimulated group. The statistical significance of differences observed was determined by Wilcoxon matched-pairs signed-rank test. (**B**) ELISA of IFN-γ level in the culture supernatants from PHA-stimulated proliferation assay in both COPD patients and non-COPD subjects. Data are expressed as mean ± SEM (n=12). \**P*\<0.05 vs non-COPD subjects. The statistical significance of differences observed was determined by Mann--Whitney test.\
**Abbreviations:** con, control; IFN, interferon; LIR, liraglutide; N.D., not detectable; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; SEM, standard error of the mean.](copd-13-3191Fig4){#f4-copd-13-3191}

![PD-1 expression of T cells in COPD patients.\
**Notes:** (**A**, **B**) Frequency of PD-1 expression on CD4 T cells and CD8 T cells measured by flow cytometry from COPD with or without LIR treatment overnight (n=10). Each line represents a result from an individual COPD patient. \*\**P*\<0.01 vs control. The statistical significance of differences observed was determined by Wilcoxon matched-pairs signed-rank test. (**C**, **D**) Frequency of PD-1 expression on CD4 T cells and CD8 T cells measured by flow cytometry at baseline from COPD patients (n=17) and non-COPD subjects (n=16). Data are \* expressed as mean ± SEM. \**P*\<0.05 vs non-COPD subjects. The statistical significance of differences observed was determined by the Mann--Whitney test.\
**Abbreviations:** con, control; LIR, liraglutide; PD-1, programmed cell death protein 1; SEM, standard error of the mean.](copd-13-3191Fig5){#f5-copd-13-3191}

###### 

Characteristics of all included subjects

  Characteristics                Non-COPD                     COPD                        P-value
  ------------------------------ ---------------------------- --------------------------- -------------
                                                                                          
  **For GLP-IR expression**      **n**=**35**                 **n**=**40**                
  Age (years)                    66.89±1.63 (58, 74)          68.18±1.64 (60, 75.5)       NS
  Sex (male:female)              35:0                         40:0                        
  Body mass index (kg/m^2^)      22.53±0.37 (20.8, 24.61)     21.14±0.60 (18.31, 24.07)   NS
  Current:ex-smokers (n)         25:10                        32:8                        NS
  Smoking history (pack-years)   37.86±3.04 (25, 45)          48.85±4.62 (30, 60)         NS
  ICs (%)                        --                           40                          
  FEV~1~% predicted              94.48±2.29 (84.22, 99)       46.82±2.61 (34.13, 57.93)   *P*\<0.0001
  FEV~1~/FVC (%)                 85.44±1.27 (80.78, 93)       55.45±1.84 (47.56, 66.5)    *P*\<0.0001
  **For PD-I expression**        **n**= **16**                **n**=**17**                
  Age (years)                    63.43±2.28 (59.5, 68.5)      67.47±2.17 (60, 74)         NS
  Sex (male:female)              16:0                         17:0                        
  Body mass index (kg/m^2^)      22.53±0.37 (20.8, 24.61)     21.14±0.60 (18.31, 24.07)   NS
  Current:ex-smokers (n)         16:0                         17:0                        
  Smoking history (pack-years)   37.86±3.58 (25, 50)          44.29±5.88 (30, 48.75)      NS
  ICs (%)                        --                           41.2                        
  FEV~1~% predicted              97.49±4.45 (84.75, 105)      45.34±3.75 (36, 53)         *P*\<0.0001
  FEV~1~/FVC (%)                 87.31 ±1.89 (81.54, 93.62)   55.97±3.52 (47, 67.25)      *P*\<0.0001
  **For PHA stimulation**        **n**=**12**                 **n**=**12**                
  Age (years)                    63.17±1.80 (57, 68.5)        67.42±1.58 (62.5, 72.5)     NS
  Sex (male:female)              12:0                         12:0                        
  Body mass index (kg/m^2^)      23.23±1.04 (20.29, 25.93)    23.45±1.10 (21.18, 26.04)   NS
  Current:ex-smokers (n)         12:0                         12:0                        
  Smoking history (pack-years)   44.17±4.84 (31.25, 57.5)     40.42±6.78 (21.25, 53.75)   NS
  ICs (%)                        --                           0                           
  FEV~1~% predicted              96.5±3.27 (85.25, 100.8)     41.73±3.98 (27.95,49.75)    *P*\<0.0001
  FEV~1~/FVC (%)                 83.09±2.20 (74.76, 90.67)    53.27±3.83 (40.18, 68.38)   *P*\<0.0001

**Notes:** Data are presented as mean ± SEM (IQR) unless otherwise stated. ICS (%), proportion of COPD patients using ICS as a current maintenance drug for at least 3 months; IQR, IQR (p25, p75).

**Abbreviations:** GLP-1R, glucagon-like peptide-1 receptor; ICS, inhaled corticosteroid; LIR, liraglutide; NS, not significant; PD-1, programmed cell death protein 1; SEM, standard error of mean.
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